ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Our drug candidates target specific chemokines or chemo-attractant receptors, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. Our goal is to discover, develop and commercialize therapeutics with distinct advantages over currently marketed therapies in our disease areas of focus, thereby maximizing shareholder value.
2:44 PM ET on Mar 27, 2015
Delayed at least 20 minutes.
Provided by eSignal.
Mar 12, 2015
ChemoCentryx Reports Fourth Quarter 2014 Financial Results and Provides Corporate Update
Feb 26, 2015
ChemoCentryx to Hold Fourth Quarter 2014 Financial Results Conference Call on Thursday, March 12, 2015
Feb 17, 2015
ChemoCentryx to Present at the Cowen and Company 35th Annual Health Care Conference
^ Return to Top